Do you want to read an article? Please log in or register.
Exhaled volatile organic compounds detect pulmonary exacerbations early in children with cystic fibrosis: results of a 1 year observational pilot study
Further Publications
RECOMMENDED
Related content
RECOMMENDED
Pulmonary Fibrosis
Exhaled Volatile Organic Compounds analysis by e-nose can detect Idiopathic Pulmonary Fibrosis
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
doi: 10.1088/1752-7163/ab8c2e.
RECOMMENDED
Pulmonary Fibrosis
Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study
Lancet Respir Med.
McNamara JJ, McColley SA, Marigowda G, Liu F, Tian S, Owen CA, Stiles D, Li C, Waltz D, Wang LT, Sawicki GS
doi: 10.1016/S2213-2600(18)30460-0.
Lung clearance index to monitor treatment response in pulmonary exacerbations in preschool children with cystic fibrosis
Thorax.
Rayment JH, Stanojevic S, Davis SD, Retsch-Bogart G, Ratjen F
doi: 10.1136/
RECOMMENDED
Pulmonary Fibrosis
BAL inflammatory markers can predict pulmonary exacerbations in children with cystic fibrosis
★ 2
Recommended by
Dr Martin Frey, Faculty Member
Chest.
Ishak A, Stick SM, Turkovic L, Ranganathan SC, King L, Harrison J, Sly PD, Caudri D, Schultz A, AREST CF.
doi: 10.1016/j.chest.2020.06.044.
RECOMMENDED
Pulmonary Fibrosis
Inhaled antibiotics for pulmonary exacerbations in cystic fibrosis
Cochrane Database Syst Rev.
Smith S, Rowbotham NJ, Charbek E
doi: 10.1002/14651858.
RECOMMENDED
Pulmonary Fibrosis
Prevalence and clinical associations of Staphylococcus aureus small-colony variant respiratory infection in children with cystic fibrosis (SCVSA): a multicentre, observational study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Lancet Respir Med.
Wolter DJ, Onchiri FM, Emerson J, Precit MR, Lee M, McNamara S, Nay L, Blackledge M, Uluer A, Orenstein DM, Mann M, Hoover W, Gibson RL, Burns JL, Hoffman LR, SCVSA study group.
doi: 10.1016/S2213-2600(19)30365-0.Visit the original publication at ncbi.nlm.nih.gov
RECOMMENDED
Pulmonary Fibrosis
Outcomes and endpoints reported in studies of pulmonary exacerbations in people with cystic fibrosis: A systematic review
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
J Cyst Fibros
McLeod C, Wood J, Schultz A, Norman R, Smith S, Blyth CC, Webb S, Smyth AR, Snelling TL
doi: 10.1016/j.jcf.2020.08.015
First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results
Swiss Med Wkly.
Murer C, Huber LC, Kurowski T, Hirt A, Robinson CA, Bürgi U, Benden C
doi: 10.4414/smw.2018.14593.
RECOMMENDED
Pulmonary Fibrosis
Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial
Am J Respir Crit Care Med.
Mayer-Hamblett N, Retsch-Bogart G, Kloster M, Accurso F, Rosenfeld M, Albers G, Black P, Brown P, Cairns A, Davis SD, Graff GR, Kerby GS, Orenstein D, Buckingham R, Ramsey BW; OPTIMIZE Study Group
doi: 10.1164/rccm.